Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.53
+5.12 (2.10%)
AAPL  272.36
+3.89 (1.45%)
AMD  246.38
+12.84 (5.50%)
BAC  53.59
+0.39 (0.73%)
GOOG  289.46
+9.76 (3.49%)
META  633.30
+11.59 (1.86%)
MSFT  504.60
+7.78 (1.57%)
NVDA  195.57
+7.42 (3.94%)
ORCL  244.03
+4.78 (2.00%)
TSLA  441.74
+12.22 (2.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.